Nitric oxide (NO) is an important inflammatory mediator in nonhuman animal models of rheumatoid arthritis (RA). The purpose of the present study was to determine whether blood mononuclear cells from patients with active RA (as compared to control subjects) have higher levels of NO synthase type 2 (NOS2) and produce more NO in vitro. Leukocytes from 25 RA patients and 20 normal subjects were examined. Arthritis activity was assessed by tender and swollen joint counts, duration of morning stiffness, patient assessment of pain, physician and patient global assessment of disease activity, the modified Stanford Health Assessment Questionnaire, and by blood levels of acute phase reactants. Blood mononuclear cell NOS enzyme activity/antigen content and nitrite/nitrate formation in vitro were measured. Blood mononuclear cells from RA patients had increased NOS activity and increased NOS2 antigen content as compared to those from normal subjects, and responded to interferon-'y with increased NOS expression and nitrite/nitrate production in vitro. NOS activity of freshly isolated blood mononuclear cells correlated significantly with disease activity, as assessed by tender and swollen joint counts. Our results demonstrate that patients with RA have systemic activation for NOS2 expression, and that the degree of activation correlates with disease activity. Increased NOS2 expression and NO generation may be important in the pathogenesis of RA. R heumatoid arthritis (RA) is a chronic systemic disease of unknown etiology that is characterized by joint inflammation and progressive loss of articular cartilage and subchondral bone (1). Prominent pathologic features of joint inflammation are synovial proliferation and mononuclear cell infiltration, which are believed to result from dysregulated production of cytokines, growth factors, cell adhesion molecules, and nonprotein mediators, such as arachidonic acid metabolites and reactive oxygen species (2-4).
R
heumatoid arthritis (RA) is a chronic systemic disease of unknown etiology that is characterized by joint inflammation and progressive loss of articular cartilage and subchondral bone (1) . Prominent pathologic features of joint inflammation are synovial proliferation and mononuclear cell infiltration, which are believed to result from dysregulated production of cytokines, growth factors, cell adhesion molecules, and nonprotein mediators, such as arachidonic acid metabolites and reactive oxygen species (2) (3) (4) .
Nitric oxide (NO) may be a critical mediator in this inflammatory cascade (5, 6) . NO is generated endogenously from L-arginine by oxidation to L-citrulline and NO. This reaction is catalyzed by a group of three related NO synthase (NOS) enzymes that are encoded by separate genes (neural NOS [NOS1], endothelial NOS [NOS3], and inducible NOS or NOS type 2 [NOS2]). Increased NOS2 expression and NO production have been noted in induced and spontaneous nonhuman animal models of arthritis, and inhibitors of NOS can reduce arthritis in these conditions (6) (7) (8) (9) (10) (11) (12) . Moreover, serum and synovial fluid from humans with inflammatory arthritides have increased levels of NO catabolites (13) (14) (15) . Also, synovial tissue from humans with inflammatory arthritis express NOS2 mRNA and protein, and generate NO in vitro (16) .
The purpose of the present study was to determine whether blood mononuclear cells from patients with active RA have enhanced expression of NOS2 and enhanced capability to produce NO in vitro. We report results of work that couples detailed clinical and laboratory rheumatological studies with research laboratory measurements of NOS expression and NO production.
Materials and Methods
Subjects. 25 patients who met the American Rheumatism Association 1987 revised criteria for the classification of RA (17) were recruited from the rheumatology outpatient clinics at the Duke University Medical Center (DUMC). To be eligible for this study, doses ofprednisone (~< 10 mg/d) and nonsteroidal antiinflammatory drugs (NSAIDS) in RA patients must have been stable for at least 2 wk before entry. Concomitant use of secondline drugs such as methotrexate, gold, sulfasalazine, hydroxychloroquine, and azathioprine was permitted if the doses had been stable for at least 4 wk before the study. 20 age (-+5 yr)-and gen- der-matched control subjects without tLA were recruited by newspaper advertising. The study protocol was approved by the DUMC Institutional Review Board. Informed consent was obtained from each subject before participation.
Patients and controls were excluded if they had a coexisting chronic inflammatory condition, active infection, malignancy, cirrhosis, or a serum creatinine >2.5 mg/dl. Pregnant women were excluded because of reports of elevated NO production in pregnancy (181. Use of nitroglycerin, other nitrate-containing medications, and tobacco products was prohibited during the study.
Study Design. Eligible subjects were evaluated in the General
Clinical Research Center (GCRC) at DUMC. A medical history and physical examination were done on adnfission to confirm subject eligibility, tLA patients underwent a clinical arthritis assesslneut using the t:bllowing disease measures: tender and swollen joint count (with a nlaxinmm of 68 tender and 66 swollen joints), duration of lnorning stiffness (minutes), patient assessment of pain (10 cm visual analogue scale), physician and patient global assesslnent of" disease activity (10 cm visual analogue scale), and the modified Stanford Health Assessment Questionnaire (HAQ; 19) .
A complete blood count and routine laboratory values, including serum creatinine and albumiu, were obtained upon entry. The erythrocyte sedimentation rate (ESR) and C-reactive protein (CI/,P), indices of KA disease activity, were lneasured in both patients and controls.
Blood ?llom, uMear Cell Pn'panltio,. 40 (specific gravity = 1.077). Leukocyte-free platelets were prepared as noted before (20) . NTtrite /nitrate, NO Synthase Enz),me Activit),, and Antigen A,alyses. Since NO is rapidly oxidized to nitrite/nitrate, stable inorganic nitrogen oxides, levels of these catabolites have been used as an indicator of NO production. Nitrite/nitrate levels in supernatant media were measured as described (22, 23) . Cellular extracts were prepared and analyzed for NOS activity (14-C-L-arginine conversion to 14-C-t-citrulline) and antigen content by inmmnoblot, as described earlier (23) . hnnmnoblots were done using a monoclonal anti-NOS2 antibody (Transduction Laboratories, Lexington, KY; 23) and the enhanced chenfiluminescence reagents from Amersham (Arlington Heights, ILl. 
StatisticalA,all,scs.
Descriptive statistics are expressed in terms of the median and interquartile range for COlmUUOUS variables and as the number and percent of subjects fbr categorical variables. Comparisons between cases and controls were made with thc Wilcoxon rank-sum test tbr continuous variables and with a chisquare test of homogeneity for categorical variables. Within-subject comparisons used the Quade test (24) , a generalization of the Wilcoxon signed-rank test. 25 tLA patients and 20 healthy controls were eligible for the study. Characteristics o f the patients and controls are described in Table 1 . ILA patients generally had long-standing, severe disease, as evidenced by their use o f multiple second-line drugs, and the relatively high prevalence o f serum rheumatoid factor positivity and subcutaneous nodules. Most o f the R A patients were receiving multiple arthritis medications. Approximately half o f the ILA patients were taking an N S A I D , while only 2 o f the 20 controls were taking a medication from this class o f antiinflammatory agents. O f the 25 R A patients, 18 (72%) and 16 (64%) were receiving c o n c o m i t a n t second-line drug and low dose prednisone therapy, respectively. Despite treatment with these agents, the 1LA patients exhibited tnoderate disease activity, as shown by high tender and swollen joints counts, long durations o f m o r n i n g stiffness, moderately high levels o f functional disability, as measured by the H A Q , and elevated levels o f the acute phase reactants ESP, and CtLP (Table 2) .
Results

Patient Characteristics.
NOS Enzyme Activity in Blood Mononuclear Cells.
N O S activity was measured in freshly isolated and cultured cells from tLA patients and controls. Freshly isolated ceils from 1LA patients had significantly higher levels o f N O S activity than did the cells from control subjects (P <0.004) (Fig. 1 A) . T h e numbers o f monocytes in the freshly isolated m o n o n u c l e a r ceils were essentially identical in the two groups: 59 (21) lymphocytes contain little or no NOS activity (5, 26) . Inclusion of 2 mM NQmonomethyl-r-arginine in the NOS assay reduced the conversion of L-arginine to t-citrulline by >90%. To assess the responsiveness of blood mononuclear cells to immune stimulation, isolated cells from controls and RA patients were cultured without additives, with LPS alone, IFN-'y alone, or the combination for 5 d. NOS activity in the cultured, untreated cells from RA patients was twofold greater than that in controls (Fig. 1 A) , indicating that the cells from RA patients retained increased NOS activity, even after 5 d of in vitro culture. In agreement with our previous observations (23) , treatment of cells from controls with LPS alone, IFN-'y alone, or the combination in vitro did not augment NOS activity. However, cells from RA patients cultured in vitro with IFN-'y alone or IFN-w + LPS exhibited significantly increased NOS activity (Fig. 1  A) . Comparable to the increases in NOS activity in RA cells, supernatant media from the RA cells cultured with LPS or LPS + IFN-y contained more nitrite/nitrate than did those from control subjects ( Fig. 1 /3 ).
NOS Antigen Expression. Freshly isolated cells from each
control subject and RA patient were analyzed by immunoblot for NOS2 antigen expression. Cell lysates from 19 of the 25 RA patients contained a protein (130-131 kD) that reacted with the anti-NOS2--specific antibody, while only 3 of 20 from controls displayed the antigen on blot (P <0.0001). There was no reaction with an isotypematched (IgG2a) control Ig. Relationship between NOS Activity, Medications, and Disease Measures. RA patients had increased NOS activity relative to control subjects, despite concomitant use of medications that might inhibit this enzyme. The 13 patients taking NSAIDS had lower NOS activity (pmol citrulline/mg) in their freshly isolated cells (27 [15] , median [interquartile range]) than did the 12 patients not taking NSAIDS (39 [32] ). The 16 patients receiving prednisone had comparable NOS activity (31 [26] ) to the 9 patients not receiving prednisone (32 [55] ). NOS activity in the 9 RA patients taking methotrexate (39 [33] ) was higher than that for the 16 patients not taking methotrexate (31 [22] ). Because of the complexity of the drug regimens (several patients were taking multiple medications) and small numbers of subjects in the different groups, these results were not analyzed statistically.
NOS activity of freshly isolated cells was investigated as correlates of traditional clinical and laboratory indices of disease activity. No significant relationship was found between NOS activity and the HAQ score, physician and patient global assessment of disease activity, patient pain scale, or levels of the acute phase reactants ESR and CRP. NOS activity of freshly isolated blood cells, however, was positively correlated with the tender joint counts (r = 0.48) and swollen joint counts (r = 0.47) (P <0.02 for each), indicating a possible relationship between blood cell NOS activity and the extent of joint inflammation.
Discussion
Our study documents that mononuclear blood cells from RA patients are activated for systemic NO overproduction. Patients have increased NOS enzyme activity and NOS2 antigen in freshly isolated blood mononuclear cells. Furthermore, when cultured in vitro, cells from RA patients respond to LPS, IFN-% or the combination of both by increasing their levels of NOS activity and NO production, while cells from controls do not. Our data provide new information indicating the potential importance of NOS2 and NO in the pathogenesis of RA, and they raise the possibility that excess NOS2 expression and NO production could be targeted for therapy in humans with RA.
Although previous studies of blood monocytes in RA patients have noted systemic activation for the generation of reactive oxygen species generation, prostanoids, IL-I, TNF, and neopterin (27) (28) (29) , our work is the first to demonstrate systemic activation of blood mononuclear cells in this disease for NOS expression and NO production. NO is an important inflammatory mediator in nonhuman animal models of inflammatory arthritis; these include adjuvant arthritis, collagen-induced arthritis, and spontaneous arthritis in autoimmune MRL-lpr/lpr mice (6, 11, 30) .
Likewise, NO participates in the pathogenesis of spontaneous myositis in the SJL mouse (31) . NO has been reported to be increased in the synovial fluid and sera of patients with RA (13, 15, 32) ; however, some of these studies are difficult to evaluate because the subjects' oral intake of nitrite and nitrate (NO catabolites measured by the investigators) was not limited and quantitated. Kaur and Halliwell showed increased levels of nitrotyrosine (a product resulting from peroxynitrite action) in serum and synovial fluid from arthritis patients (14) . Investigators have recently reported that synovial tissues from patients with RA and osteoarthritis produce NO in vitro, and express NOS2 mRNA (reverse transcription-PCR) and protein (immunoblot and immunohistology). NOS2 was associated primarily with CD14 + cells (mononuclear phagocytes; 16). In RA, blood monocytes are recruited to synovial tissues. Recently emigrated monocytes may be activated for NOS expression and NO production in the synovium (16) . Also, monocytes activated for NOS expression and NO production in the circulation may emigrate to the synovium where they may initiate and propagate inflammation.
NO has many actions that are appropriate for a proinflammatory agent. It is made by numerous cell types in sites of inflammation, and it increases blood flow and vascular permeability. NO has cell and tissue-destructive abilities; it can also induce cyclooxygenase, cause pain, destroy certain protease inhibitors, and enhance IL-1, TNF, and NADPH oxidase activities in myeloid cells (6, 33) . NO production may be augmented by several substances, including cytokines, growth factors, immune complexes, and bacterial products. Since superoxide (02-) may convert NO to peroxynitrite (a potent proinflammatory molecule [34, 35] ), coincident production of NO and O~-may further amplify the inflammatory state. In the joint, several cell types can produce NO--mononuclear phagocytes, chondrocytes, endothelial cells, and possibly others. Mononuclear phagocytes and chondrocytes are the most likely sources in the joint. Human articular chondrocytes produce relatively high levels of NO in response to cytokines (11, 36, 37) . If NO is a vital mediator of joint inflammation in RA, then blocking NO production by NOS2-specific inhibitors and blocking NO effects by NO quenchers may have therapeutic roles in RA.
